- Home
- LXP vs OGN Comparison
LXP vs OGN Comparison
Compare LXP & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXP
- OGN
- Stock Information
- Founded
- LXP 1993
- OGN 1923
- Country
- LXP United States
- OGN United States
- Employees
- LXP N/A
- OGN N/A
- Industry
- LXP Real Estate Investment Trusts
- OGN Biotechnology: Pharmaceutical Preparations
- Sector
- LXP Real Estate
- OGN Health Care
- Exchange
- LXP Nasdaq
- OGN Nasdaq
- Market Cap
- LXP 2.5B
- OGN 2.5B
- IPO Year
- LXP 1993
- OGN N/A
- Fundamental
- Price
- LXP $9.16
- OGN $10.39
- Analyst Decision
- LXP Hold
- OGN Hold
- Analyst Count
- LXP 3
- OGN 4
- Target Price
- LXP $10.50
- OGN $18.00
- AVG Volume (30 Days)
- LXP 3.2M
- OGN 3.8M
- Earning Date
- LXP 11-05-2025
- OGN 10-30-2025
- Dividend Yield
- LXP 5.93%
- OGN 0.77%
- EPS Growth
- LXP 203.57
- OGN N/A
- EPS
- LXP 0.27
- OGN 2.69
- Revenue
- LXP $363,003,000.00
- OGN $6,281,000,000.00
- Revenue This Year
- LXP N/A
- OGN N/A
- Revenue Next Year
- LXP $5.19
- OGN $1.36
- P/E Ratio
- LXP $33.72
- OGN $3.86
- Revenue Growth
- LXP 6.63
- OGN N/A
- 52 Week Low
- LXP $6.85
- OGN $8.01
- 52 Week High
- LXP $10.43
- OGN $22.42
- Technical
- Relative Strength Index (RSI)
- LXP 68.57
- OGN 66.34
- Support Level
- LXP $8.82
- OGN $8.95
- Resistance Level
- LXP $9.10
- OGN $9.64
- Average True Range (ATR)
- LXP 0.20
- OGN 0.33
- MACD
- LXP 0.05
- OGN 0.12
- Stochastic Oscillator
- LXP 90.00
- OGN 97.96
About LXP LXP Industrial Trust (Maryland REIT)
LXP Industrial Trust is a real estate investment trust principally involved in the ownership of equity and debt investments in single-tenant properties and land throughout the United States. The majority of the revenue is earned through rental revenue.
About OGN Organon & Co.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.